Evidence map›Paper›PMID 34535959›Full record

Trial reportJournal of cachexia, sarcopenia and muscle2021

Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients.

Laurence Genton, Menno Pruijm, Daniel Teta, Isabelle Bassi, Patrice D Cani, Nadia Gaïa, François R Herrmann, Nicola Marangon, Julie Mareschal, Giulio G Muccioli and 5 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Gut microbes · 2026
    Article
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Laurence GentonUnit of Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.ORCID 0000-0002-0037-5203
Menno PruijmService of Nephrology, University Hospitals of Lausanne and University of Lausanne, Lausanne, Switzerland.
Daniel TetaService of Nephrology, Cantonal Hospital of Sion, Sion, Switzerland.
Isabelle BassiService of Nephrology, Cantonal Hospital of Sion, Sion, Switzerland.
Patrice D CaniLouvain Drug Research Institute, Metabolism and Nutrition Research Group, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Université catholique de Louvain, Brussels, Belgium.
Nadia GaïaGenomic Research Lab and Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
François R HerrmannDepartment of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Nicola MarangonService of Nephrology, Geneva University Hospitals and Clinique of Champel, Geneva, Switzerland.
Julie MareschalUnit of Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Giulio G MuccioliLouvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Université catholique de Louvain, Brussels, Belgium.
Catherine StoermannService of Nephrology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Francesco SurianoLouvain Drug Research Institute, Metabolism and Nutrition Research Group, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Université catholique de Louvain, Brussels, Belgium.
Arlene Wurzner-GhajarzadehService of Nephrology, University Hospitals of Lausanne and University of Lausanne, Lausanne, Switzerland.
Vladimir LazarevicGenomic Research Lab and Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Jacques SchrenzelGenomic Research Lab and Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
University of Geneva · CHHôpital de Sion · CHUniversity of Lausanne · CHWalloon Excellence in Lifesciences and Biotechnology · BEUCLouvain · BE

Funding

Swiss National Science Foundation 320030_163144
6 · The paper itself

Abstract

backgroundWe have previously shown that glycine increases fat-free mass in chronic haemodialysis patients with features of malnutrition as compared with branched-chain amino acids (BCAAs). This multicentre randomized double-blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota.

methodsHaemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests.

resultsWe analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin-6 (P = 0.002), glucagon-like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero-radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1-Q3 0.008-0.078 vs. 0.004; Q1-Q3 0.001-0.070) and Bifidobacterium dentium (0.0247; Q1-Q3 0.002-0.191 vs. 0.003; Q1-Q3 0.001-0.086) significantly decreased with the BCAA supplementation.

conclusionsThe BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium.

Indexed as

GlycineMicrobiotaAmino Acids, Branched-ChainCross-Over StudiesDietary SupplementsHumansRenal DialysisRNA, Ribosomal, 16SAmino Acids, Branched-ChainGlycineRNA, Ribosomal, 16SAppetiteBranched-chain amino acid malnutritionEndocannabinoidsGlycineGut microbiota

Identifiers

PMID34535959
PMCPMC8718035
OpenAlexW3200971797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.